Gene therapy developer Neurogene's Q3 net loss widens

Neurogene

13/11/2025 22:20

Overview

Company maintains strong cash position, funding operations through Q1 2028

Net loss for Q3 2025 was $21.0 mln, slightly higher than Q3 2024

Outlook

Neurogene's cash position expected to fund operations through Q1 2028

Result Drivers

R&D expenses were $17.2 million for the three months September 30, 2025 compared to $16.3 million for the three months ended September 30, 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.99
Q3 Net Income
-$20.95 mln
Q3 Operating Expenses
$23.80 mln
Q3 Operating Income
-$23.80 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Neurogene Inc is $60.00, about 55.9% above its November 13 closing price of $26.49

Press Release: ID:nBw5Tryj8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)